Association Between SGLT2 Inhibitor Treatment and Diabetic Ketoacidosis and Mortality in People With Type 2 Diabetes Admitted to Hospital With COVID-19.

Saved in:

Bibliographic Details
Title:	Association Between SGLT2 Inhibitor Treatment and Diabetic Ketoacidosis and Mortality in People With Type 2 Diabetes Admitted to Hospital With COVID-19.
Authors:	Khunti, Kamlesh¹ kk22@le.ac.uk, Ruan, Yue^2,3, Davies, Jim^2,4, Field, Benjamin C.T.^5,6, Harris, Sophie⁷, Kosiborod, Mikhail^8,9, Nagi, Dinesh¹⁰, Narendran, Parth^11,12, Patel, Dipesh¹³, Ryder, Robert E.J.¹⁴, Várnai, Kinga A.^2,15, Wild, Sarah H.¹⁶, Wilmot, Emma G.^17,18, Rea, Rustam^2,3, ReaRustamWilmotEmmaKhuntiKamleshWildSarahFieldBenNarendranParthGandhiRajivHarrisSophieNagiDineshRyderRobertDaviesJimHarrisSteveFreemanOliverMaylorBenVárnaiKinga A.RoadknightGailCullMelissaRuanYueEdwardsAmyGeldingSusanGunganahKirunAungPyeiBanerjeeMoul, Wilmot, Emma, Wild, Sarah, Field, Ben, Gandhi, Rajiv, Ryder, Robert
Source:	Diabetes Care. Dec2022, Vol. 45 Issue 12, p2838-2843. 6p. 1 Diagram, 2 Charts.
Database:	Academic Search Ultimate

Description
ISSN:	01495992
DOI:	10.2337/dc22-0357